tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SMS Lifesciences Announces Dividend Record Date and Launches Shareholder Engagement Campaign

Story Highlights
  • SMS Lifesciences sets September 24, 2025, as the record date for its 2024-25 dividend.
  • The company launches ‘Saksham Niveshak’ to update shareholder details and claim dividends.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
SMS Lifesciences Announces Dividend Record Date and Launches Shareholder Engagement Campaign

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

SMS Lifesciences India Ltd. ( (IN:SMSLIFE) ) has provided an announcement.

SMS Lifesciences India Ltd. has announced the record date for its 2024-25 dividend as September 24, 2025, with the dividend payment subject to shareholder approval at the upcoming AGM on September 30, 2025. Additionally, the company has launched the ‘Saksham Niveshak’ campaign to engage shareholders in updating KYC details and claiming unclaimed dividends, aligning with regulatory compliance and investor empowerment initiatives.

More about SMS Lifesciences India Ltd.

SMS Lifesciences India Ltd. operates in the pharmaceutical industry, focusing on the production and supply of active pharmaceutical ingredients (APIs) and intermediates. The company is dedicated to providing high-quality products and services to its clients, with a strong emphasis on compliance and innovation.

Average Trading Volume: 459

Technical Sentiment Signal: Buy

Current Market Cap: 3.35B INR

Find detailed analytics on SMSLIFE stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1